UNSPSC 51372200: Controlled substance analgesic morpholines

Controlled substance analgesic drugs made from tetrahydro-1,4-oxazines.

UNSPSC 51372200 Controlled substance analgesic morpholines is a Class code covering pharmaceutical procurement by state and local health agencies, typically including naloxone, prescription opioid alternatives, and related medications supplied through competitive bidding or cooperative purchasing agreements. State and local governments soliciting under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions to negotiate volume pricing with manufacturers and authorized wholesalers. The work involves procuring finished pharmaceutical products with specified National Drug Codes (NDC), managing relationships with licensed pharmaceutical distributors, and ensuring compliance with FDA requirements, cGMP certification, and Drug Supply Chain Security Act (DSCSA) standards.

Recent activity concentrates in Florida and Texas, with national reach through multistate cooperative agreements. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: this due date appears to be a historical error in the source record). The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage procurement planning. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring manufacturers to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) and to maintain comprehensive insurance coverage including $5,000,000 commercial general liability. All three solicitations emphasize electronic submission, compliance with federal drug-supply regulations, and fixed-fee or negotiated pricing structures with administrative fees or rebate models.